Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BI 3923948 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on BI 3923948 (Feb 2026). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BI 3923948 | BI-3923948|BI3923948 | Limited information is currently available on BI 3923948 (Feb 2026). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07395258 | Phase I | BI 3923948 BI 3923948 + Ezabenlimab | A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors) | Not yet recruiting | USA | SWE | FRA | ESP | DEU | 0 |